Compare WMS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMS | TGTX |
|---|---|---|
| Founded | 1966 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.5B |
| IPO Year | 2014 | 2008 |
| Metric | WMS | TGTX |
|---|---|---|
| Price | $139.08 | $51.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $180.63 | $49.80 |
| AVG Volume (30 Days) | 537.9K | ★ 2.0M |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 5.44 | 0.12 |
| Revenue | ★ $3,050,376,000.00 | $2,785,000.00 |
| Revenue This Year | $5.23 | $49.08 |
| Revenue Next Year | $12.79 | $26.69 |
| P/E Ratio | ★ $25.37 | $447.08 |
| Revenue Growth | ★ 5.03 | N/A |
| 52 Week Low | $112.67 | $25.37 |
| 52 Week High | $179.32 | $59.30 |
| Indicator | WMS | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 45.12 |
| Support Level | $130.46 | $51.22 |
| Resistance Level | $154.50 | $58.34 |
| Average True Range (ATR) | 4.09 | 2.16 |
| MACD | -1.12 | -0.72 |
| Stochastic Oscillator | 15.05 | 12.55 |
Advanced Drainage Systems Inc designs, manufactures and markets water management solutions in the stormwater and onsite wastewater industries, providing superior drainage solutions for use in the construction and agriculture markets. The company's products are used across a broad range of end markets and applications, including non-residential, residential, infrastructure and agriculture applications. It has two reportable segments: Stormwater and Wastewater. It derives the majority of revenue from the Stormwater segment, which manufactures and markets thermoplastic corrugated pipe and complementary products, including single wall pipe, N-12 HDPE pipe, polypropylene pipe, StormTech, Nyloplast, Inserta Tee, water quality filters and structures, and NDS channel drains, and access boxes.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.